Cara Current Deferred Revenue from 2010 to 2024
| CARA Stock | USD 0.26 0.01 3.70% |
Current Deferred Revenue | First Reported 2012-12-31 | Previous Quarter -8 M | Current Value -168 K | Quarterly Volatility 12.8 M |
Check Cara Therapeutic financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cara Therapeutic's main balance sheet or income statement drivers, such as Depreciation And Amortization of 246.1 K, Interest Expense of 1 M or Selling General Administrative of 15.7 M, as well as many indicators such as Price To Sales Ratio of 1.82, Dividend Yield of 0.0 or PTB Ratio of 0.67. Cara financial statements analysis is a perfect complement when working with Cara Therapeutic Valuation or Volatility modules.
Cara | Current Deferred Revenue |
Latest Cara Therapeutic's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Cara Therapeutic over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Cara Therapeutic's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cara Therapeutic's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Cara Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 16,995,778 | |
| Geometric Mean | 7,856,248 | |
| Coefficient Of Variation | 68.91 | |
| Mean Deviation | 10,516,385 | |
| Median | 22,262,000 | |
| Standard Deviation | 11,712,459 | |
| Sample Variance | 137.2T | |
| Range | 26.5M | |
| R-Value | 0.78 | |
| Mean Square Error | 57.1T | |
| R-Squared | 0.61 | |
| Significance | 0.0006 | |
| Slope | 2,051,662 | |
| Total Sum of Squares | 1920.5T |
Cara Current Deferred Revenue History
About Cara Therapeutic Financial Statements
Cara Therapeutic stakeholders use historical fundamental indicators, such as Cara Therapeutic's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Cara Therapeutic investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cara Therapeutic's assets and liabilities are reflected in the revenues and expenses on Cara Therapeutic's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cara Therapeutic. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 25.6 M | 26.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cara Therapeutic offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cara Therapeutic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cara Therapeutic Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cara Therapeutic Stock:Check out the analysis of Cara Therapeutic Correlation against competitors. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.71) | Revenue Per Share 0.202 | Quarterly Revenue Growth (0.86) | Return On Assets (0.63) | Return On Equity (1.84) |
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.